Search results
FDA approves Alecensa as leading-edge adjuvant therapy for ALK-positive lung cancer
Clinical Trials Arena via Yahoo Finance· 2 days agoOn 18 April 2024, the US Food and Drug Administration (FDA) approved Roche’s Alecensa (alectinib),...
Analyst Report: Exelixis, Inc.
Morningstar Research via Yahoo Finance· 15 hours agoExelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of ...
More young women are getting breast cancer. So an expert panel recommends this change
IndyStar | The Indianapolis Star via Yahoo News· 21 hours agoAs breast cancer diagnoses among young people are on the rise, experts are lowering the age at which...
Why is cancer called cancer? We need to go back to Greco-Roman times for the answer
The Conversation· 2 days agoOne of the earliest descriptions of someone with cancer comes from the fourth century BC. Satyrus, tyrant of the city of Heracleia on the Black Sea, developed a cancer ...
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 2 days agoThe company’s R&D investment strategy focuses on the area of immuno-oncology and particularly the expansion of its portfolio after the success of its...
The World is watching Tucson: Bioscience Hub
KVOA Tucson· 2 days agoThere's many reasons the world is watching Tucson. One of those reasons is the city's growth as a hub for bioscience research. One company that's taken...
What’s going on with the ImmunityBio (IBRX) stock price?
Invezz· 5 days agoImmunityBio (NASDAQ: IBRX) stock price has gone parabolic as investors cheer the recent approval of...
Novartis Is Tracking Well Above the Industry
GuruFocus.com via Yahoo Finance· 3 days agoSource: Global Cancer Observatory. Analysts...
Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal
BioPharma Dive via Yahoo Finance· 3 days agoSome have responded by changing their development strategies or pivoting to autoimmune disease...
Chasing Novo and Lilly: The obesity drugs that could challenge Wegovy and Zepbound
BioPharma Dive via Yahoo Finance· 4 days agoLarge and small drugmakers are vying for a piece of what analysts view as one of the biggest market...